BLTE today
$155.94-$0.58 (-0.37%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourBearish
15 minBearish
5 minConsolidating
Daily trend turns up above $157.47
Key levels
Resistance$166.26
Resistance$157.47
Support$150.21
Support$141.00
Latest news & SEC filings
EarningsBelite Bio Reports Unaudited Q3 2026 Financial Results
EarningsBelite Bio posts smaller Q3 loss than analysts expected
SEC FilingBelite Bio, Inc filed an insider trading report (Form 4)
All BLTE news →About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical company developing therapies for retinal degenerative diseases. Its lead candidate, tinlarebant, is being studied for Stargardt disease and geographic atrophy, with additional indications under consideration. The company operates through subsidiaries in the United States, Australia, China, Hong Kong, Taiwan, Japan, and Switzerland, and has no approved products for commercial sale.
Based on the company's 20-F filed Mar 31, 2026.
Nasdaq · Healthcare
BELITE BIO, INC (BLTE)
What Is the Price Target for BLTE?
SEPT Low Target
$200.00
SEPT Mid Target
$245.00
SEPT High Target
$303.00
Analyst Consensus
$245.00
Is BLTE a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BLTE.
Start Free Trial →Is BLTE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$245.00
12
Moat Score
NONE
4/9
Piotroski Score
312.8
Altman Z-Score
What Is Smart Money Doing with BLTE?
Insider Signal
SELLING
0 buys / 17 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Chuang Hao-Yuan | director officer | Buy | 5,000 | - | Oct 29, 2026 |
| Lin Yu-Hsin | director officer | Buy | 5,000 | - | Oct 29, 2026 |
| Scholl Hendrik Peter | officer | Sale | 200 | $33K | Oct 1, 2026 |
| Scholl Hendrik Peter | officer | Sale | 24 | $4K | Oct 1, 2026 |
| Scholl Hendrik Peter | officer | Sale | 120 | $20K | Oct 1, 2026 |
| Scholl Hendrik Peter | officer | Sale | 50 | $8K | Oct 1, 2026 |
| Scholl Hendrik Peter | officer | Sale | 78 | $13K | Oct 1, 2026 |
| Scholl Hendrik Peter | officer | Sale | 12 | $2K | Oct 1, 2026 |
| Scholl Hendrik Peter | officer | Sale | 14 | $2K | Oct 1, 2026 |
| Scholl Hendrik Peter | officer | Sale | 2 | $340.04 | Oct 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BLTE Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-95.76%
FCF Growth YoY
-26.3%
Revenue Trend
UNKNOWN
Dark Pool Trades for BLTE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BLTE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:46:31 | $156.06 | 5,000 | $$780K | SELL |
| 20:29:00 | $156.18 | 5,357 | $$837K | SELL |
| 18:16:30 | $157.15 | 3,822 | $$601K | SELL |
| 15:59:36 | $156.03 | 4,215 | $$658K | BUY |
| 15:46:48 | $156.10 | 1,500 | $$234K | BUY |
5 dark pool trades shown · $$3.1M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BELITE BIO, INC (BLTE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BLTE — frequently asked questions
What is BLTE stock price today?
BELITE BIO, INC (BLTE) is at $155.94, down 0.37% (-$0.58) at the Nov 11, 2026 close.
Why is BLTE stock moving today?
Latest BLTE news — Nov 12, 2026: Belite Bio Reports Unaudited Q3 2026 Financial Results · Nov 12, 2026: Belite Bio posts smaller Q3 loss than analysts expected
What is the BLTE price target?
The average analyst price target for BLTE is $245.00, ranging from $200 to $303, based on 7 analysts. Latest: Mizuho maintains on Sep 9, 2026.
What do analysts rate BLTE?
Analyst ratings for BLTE: 0 Buy, 12 Hold, 0 Sell — consensus Hold.
Did BLTE beat earnings?
BLTE last reported on Aug 13, 2026: EPS -$0.54 vs -$0.79 expected — a beat of 31.6%.
Does BLTE pay a dividend?
BLTE does not currently pay a dividend.
What are BLTE support and resistance levels?
Support: $150.21, $141.00, $130.00. Resistance: $157.47, $166.26, $178.44.
What are insiders doing with BLTE?
Insider activity: SELLING, 0 buys and 17 sells in the last 90 days.
What is the latest news on BLTE?
Nov 12, 2026: Belite Bio Reports Unaudited Q3 2026 Financial Results · Nov 12, 2026: Belite Bio posts smaller Q3 loss than analysts expected · Oct 30, 2026: Belite Bio, Inc filed an insider trading report (Form 4)